Shareholder Update

Find out about company announcements, latest shareholder newsletters and our recent activities in the news. more

For investor relations, please contact ir@gtgcorporate.com

A Clearer Picture of Breast Cancer Risk

1 in 11 women will develop breast cancer in their lifetime. With a market potential of $600 million per annum, BREVAGen is a cost effective test that helps women assess their sporadic
breast cancer risk.